[Homocysteine: relations to ischemic cardiovascular diseases].
Homocysteine, a sulfur-containing amino acid, is an intermediate metabolite of methionine. Patients with homocystinuria and severe hyperhomocysteinemia develop premature arteriosclerosis and arterial thrombotic events, and venous thromboembolism. Studies suggest that moderate hyperhomocysteinemia can be considered as an independent risk factor in the development of premature cardiovascular disease. In vitro, homocysteine has toxic effects on endothelial cells. Homocysteine can promote lipid peroxidation and damage vascular endothelial cells. Moreover, homocysteine interferes with the natural anticoagulant system and the fibrinolytic system. Homocysteinemia should be known in patients with premature vascular diseases, especially in subjects with no risk factors. Folic acid, vitamin B6 can lower homocysteine levels.
Piolot
A
A
Laboratoire dyslipidémies-athérosclérose, institut de recherches cliniques de Montréal, Canada.
Nadler
F
F
Parez
N
N
Jacotot
B
B
D001161:Arteriosclerosis / Q000378:metabolism / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000503:physiopathology*; D006710:Homocysteine / Q000097:blood / Q000378:metabolism* / Q000652:urine; D006801:Humans; D017202:Myocardial Ischemia / Q000378:metabolism / Q000503:physiopathology; D012307:Risk Factors
D006710:Homocysteine
L'homocystéine: ses liens avec les maladies cardiovasculaires ischémiques.